Delivery Order SPE2DB20D3303-SPE2DB25FA3WV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on September 2, 2025, with a ceiling value of $23,791.44 and firm fixed pricing. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $11,895.72 to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60 count) on August 12, 2025, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. INLYTA is a prescription pharmaceutical used in the treatment of certain cancers, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of INLYTA 5 mg tablets in a quantity of 60 units, with a ceiling value of $11,895.72. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for completion by September 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $11,923.60 to AmerisourceBergen Drug Corp for the supply of INLYTA 1 mg tablets (180-count units). This contract utilizes a firm fixed-price structure with no set-aside designation, indicating competitive award selection. The delivery order is scheduled for completion by August 15, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. INLYTA is a targeted cancer therapy...
- The Defense Logistics Agency awarded a $11,895.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of INLYTA 5 mg, a pharmaceutical product used in cancer treatment. This non-competitive delivery order, issued on September 4, 2025, will be fulfilled at the company's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. The award represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $11,895.72 to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count packaging) on September 11, 2025, with an ultimate completion date of October 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Inlyta 5 mg tablets (60-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Inlyta is a prescription medication used in oncology treatment, reflecting the federal government's ongoing pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of INLYTA 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made through competitive procurement with no set-aside...
- The Defense Logistics Agency awarded a $11,895.72 delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Inlyta 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This non-set-aside contract, awarded on July 21, 2025, utilizes firm fixed pricing and is scheduled for completion by August 11, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3WVDelivery Order
The Defense Logistics Agency awarded a $23,791.44 delivery order to AmerisourceBergen Drug Corp for 60 tablets of INLYTA 5 mg on September 18, 2025, with an ultimate completion date of October 9, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. INLYTA (axitinib) is a tyrosine kinase inhibitor used in cancer treatment, reflecting the Defense Logistics Agency Medical Supply Chain's ongoing procurement of specialized pharmaceutical products to support military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle serves as a global pharmaceutical support mechanism enabling the company to supply a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The contract structure demonstrates the Defense Logistics Agency's reliance on qualified prime vendors to efficiently deliver critical pharmaceutical products to the Defense Health Agency and other federal healthcare systems on an as-needed basis through individual delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 9/18/25 |